Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten ...

HealthDay News — As an investigation continues into a hantavirus outbreak that killed three passengers and sickened five on an ocean liner, the World Health Organization (WHO) says the odds of broader ...

Based on the current evidence, there is no consistent association between vaccines and serious or long-term health outcomes.

Relative vaccine efficacy was 26.6 percent, which met the criteria for noninferiority, superiority, higher-level superiority.

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

Botulinum toxin may slightly reduce monthly migraine days but has higher discontinuation rates due to adverse events.

Bladder-intact disease-free survival was 60% 2 years posttreatment with pembrolizumab combined with gemcitabine-based chemoradiation.

Glucagon-like peptide-1 (GLP-1) receptor agonists may be a potential novel treatment for alcohol use disorder, according to a ...

Ensitrelvir is an investigational oral antiviral under FDA review for the prevention of COVID-19 following exposure to an infected individual. It is designed to suppress the replication of SARS-CoV-2 ...

This marks a shift from years of aggressive regulation against flavored vapes after the FDA rejected marketing approvals for more than 1 million flavored products.

Topline data from the ACACIA-HCM study reveal that the cardiac myosin inhibitor aficamten met all primary and key secondary endpoints, offering a potential new treatment pathway for patients with ...

A larger percentage of patients in PFA group had treatment success at 12 months compared with those receiving antiarrhythmic-drug therapy.